TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Present at the Jefferies 2017 Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Jefferies 2017 Global Healthcare Conference in New York, NY.

When:

  Wednesday, June 7, 2017 at 2:30 PM ET
 
 

Who:

Dr. Yitzhak Peterburg, Interim President & CEO,
Dr. Michael Hayden, President of Global R&D & Chief Scientific Officer,
Dipankar Bhattacharjee, President & CEO Global Generic Medicines,
Teva Pharmaceutical Industries Ltd.
 
 

Where:

http://ir.tevapharm.com

 
 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s Website at http://ir.tevapharm.com.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

EN
06/06/2017

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and ...

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in p...

Felix Fischer ... (+3)
  • Felix Fischer
  • Josseline Jenssen
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL, AMS Osram, Teva

Felix Fischer ... (+3)
  • Felix Fischer
  • Haidje Rustau
  • Si Yong Ng

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: United Group, Altice International, Tereos, Teva, AMS Osram, Vallourec, Intrum

 PRESS RELEASE

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: ...

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’...

 PRESS RELEASE

Teva and Royalty Pharma Enter Agreement to Accelerate Development of P...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch